Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...
Palantir has been one of the best growth stories in the market. UiPath is just beginning to see its revenue growth accelerate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback